Brief: Shilpa Medicare Says US FDA Inspected Bio-Analytical Laboratory, Unit 7
01/03/2024 08:07
March 1 (Reuters) - Shilpa Medicare Ltd SHME.NS :
* USFDA INSPECTION OF BIO-ANALYTICAL LABORATORY, UNIT 7
* USFDA INSPECTION HAS BEEN CLOSED WITHOUT ANY 483
OBSERVATION
Source text for Eikon: ID:nNSE5Xvqp7
Further company coverage: SHME.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026